Comment from Emily Israel

Summary: The commenter, a patient with a systemic mast cell disease, supports the proposed action but advocates for its expansion to include inactive ingredients (excipients) on the list of bulk drug substances. They argue that including inactive ingredients is necessary to ensure patient safety, provide transparency, and account for the adverse reactions sensitive patients may experience.